Zobrazeno 1 - 10
of 60
pro vyhledávání: ''
Autor:
Helga Gardarsdottir, Patrick C. Souverein, Hendrika A. van den Ham, Yumao Zhang, Anthonius de Boer, Anke-Hilse Maitland-van der Zee
Publikováno v:
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, 86(6), 1150. NLM (Medline)
British journal of clinical pharmacology, 86(6), 1150-1164. Wiley-Blackwell
British Journal of Clinical Pharmacology, 86(6), 1150. NLM (Medline)
British journal of clinical pharmacology, 86(6), 1150-1164. Wiley-Blackwell
Aims To assess the association between concurrent use of potential pharmacokinetic or pharmacodynamic interacting drugs and major bleeding among direct oral anticoagulant (DOAC) users. Methods We performed a case-control study nested in a cohort of n
Publikováno v:
Br J Clin Pharmacol
Aims Chlorzoxazone is the paradigm marker substrate for CYP2E1 phenotyping in vivo. Because at the commonly used milligram doses (250-750 mg) chlorzoxazone acts as an inhibitor of the CYP3A4/5 marker substrate midazolam, previous attempts failed to c
Publikováno v:
British Journal of Clinical Pharmacology
Aims Quizartinib is an oral, highly potent and selective next-generation FMS-like tyrosine kinase 3 (FLT3) inhibitor under investigation in patients with FLT3-internal tandem duplication-mutated acute myeloid leukaemia. This drug-drug interaction stu
Autor:
Martin Gutierrez, Alexey V. Danilov, Shekman Wong, Lionel D. Lewis, David Chien, Suresh Agarwal, Ahmed Salem, Soham D. Puvvada, Beibei Hu
Publikováno v:
British Journal of Clinical Pharmacology. 83:846-854
Aims To examine the effect of a strong cytochrome P450 (CYP) 3A inhibitor, ketoconazole, on the pharmacokinetics, safety and tolerability of venetoclax. Methods Twelve patients with non-Hodgkin lymphoma (NHL) were enrolled in this Phase 1, open-label
Autor:
Hamim Zahir, Dolly A. Parasrampuria, Nobuko Matsushima, Kenneth E. Truitt, Jeanne Mendell, Minggao Shi
Publikováno v:
British Journal of Clinical Pharmacology
Aims Edoxaban, a novel factor Xa inhibitor, is a substrate of cytochrome P450 3 A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp). Three edoxaban drug–drug interaction studies examined the effects of P-gp inhibitors with varying degrees
Autor:
Yumi Cleary, Katja Heinig, Lutz Müller, Hasane Ratni, Omar Khwaja, Nicolas Frances, Paul Jordan, Agnès Poirier, Birgit Jaber, Tobias Bergauer, Heidemarie Kletzl, Nada Al Kotbi, Stefan Sturm, Anne Marquet, Andreas Günther, Christian Czech, Nikhat Parkar
Publikováno v:
British journal of clinical pharmacology. 85(1)
Aims Risdiplam (RG7916, RO7034067) is an orally administered, centrally and peripherally distributed, survival of motor neuron 2 (SMN2) mRNA splicing modifier for the treatment of spinal muscular atrophy (SMA). The objectives of this entry-into-human
Publikováno v:
British Journal of Clinical Pharmacology
Aims Two clinical studies were conducted to determine possible drug−drug interactions between apremilast and a strong CYP3A4 inhibitor, ketoconazole, or a potent CYP3A4 inducer, rifampicin. The main objectives of these two studies were to evaluate
Autor:
P V V S Sarma, Adegbenga Rotimi Owolabi, Cyprian O. Onyeji, James M. Cook, Julius O. Soyinka, Sharon I. Omoruyi
Publikováno v:
British Journal of Clinical Pharmacology. 69:262-270
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Malaria is widespread across some areas of the world, most of which also bear the brunt of the human immunodeficiency virus (HIV) pandemic, resulting in a high incidence of co-infection of both diseases.
Autor:
Cornelia B. Landersdorfer, Michael Rodamer, Carl M. J. Kirkpatrick, Ulrike Holzgrabe, Ulrich Jaehde, Jürgen B. Bulitta, Fritz Sörgel, Kurt G. Naber, Martina Kinzig, Andreas Reiter
Publikováno v:
British Journal of Clinical Pharmacology. 69:167-178
Probenecid influences transport processes of drugs at several sites in the body and decreases elimination of several quinolones. We sought to explore extent, time course, and mechanism of the interaction between ciprofloxacin and probenecid at renal
Autor:
Stacy S. Shord, Robert E. Molokie, Joseph R. Camp, Charles L. Baum, Hyunyoung Jeong, Eva M. Vasquez, Hui Xie, Lingtak Neander Chan
Publikováno v:
British Journal of Clinical Pharmacology. 69:160-166
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Clotrimazole troches are commonly used as prophylaxis for thrush that may develop in immunocompromised patients. • Conflicting data suggest that clotrimazole may induce or inhibit cytochrome P450 (CYP) 3